Drug Development and Approval
The House Energy and Commerce Subcommittee on Health held a hearing on ways to expedite the Food and Drug Administration’s (FDA) drug… read more
The House Energy and Commerce Subcommittee on Health held a hearing on ways to expedite the Food and Drug Administration’s (FDA) drug development and approval process. Dr. Janet Woodcock, the FDA witness in the first panel, said the agency speeds things up where it safely can but stressed that with some diseases speed was a challenge. Witnesses in the second panel of pharmaceutical and medical organization officials focused on how patients on certain drugs or clinical trials can be beneficial to the drug development and approval process in regard to making the process faster. close
People in this video
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Janet Woodcock M.D. Director U.S. Food and Drug Administration->Center for Drug Evaluation and Research
Hosting Organization
Related Video
-
Antibiotic Resistance and Drug Development
Dr. Janet Woodcock testified at a House Energy and Commerce subcommittee hearing on combating antibiotic resistance and…
-
Medicare Prescription Drug Program
Two Health and Human Services Department officials testified on reducing fraud and abuse in the Medicare Part D…
-
Fentanyl Addiction and Opioid Abuse
Federal officials and medical professionals testified on the opioid epidemic and the federal response to the drug…
-
Opioid Epidemic
State officials from Maryland, Virginia, Kentucky, and Rhode Island testified about the nation’s opioid epidemic. The…